A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

What this study is about

This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or in combination by participants with ccRCC.

Who can join (things the study team will check)

✅ You may be able to join if…

• Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC.
• For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.
• For part 2: Participants must have had at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other).
• Part 3: Participants must have had at least 1 standard treatment regimen (including a PD-1/L1 checkpoint inhibitor and/or a VEGF-TKI).
• Part 4: Participants must not have received prior systemic therapy for metastatic RCC, but may have received prior adjuvant therapy for completely resected RCC with PD-1 inhibitor if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
• Eastern Cooperative Oncology Group performance status of 0 to 1.

🚫 You may not be able to join if…

• Inability to administer and/or tolerate oral medication without chewing, breaking, crushing, or otherwise altering the product dosage form.
• Part 2A: Participants who have received more than 3 prior systemic regimens for locally advanced or metastatic ccRCC including prior treatment with HIF2a inhibitors.
• Part 2A and Part 4: Participants who have received prior treatment with belzutifan (or another HIF2a inhibitor).
• Part 3B and Part 4B: Participants who have received prior ipilimumab (or another anti-CTLA-4 containing antibody).
• Participants who have hypoxia as defined by a pulse oximeter reading < 92% at rest or requires intermittent or chronic supplemental oxygen.
• Participants who have received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 28 days prior to the first dose of study intervention.
• Part 3 and Part 4: Participants with a history of Grade ≥3 immune-mediated AEs leading to discontinuation of prior immunotherapy.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
• SCRI Oncology Partners, Nashville, Tennessee, United States
• START San Antonio, San Antonio, Texas, United States
• Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
• Gustave Roussy, Villejuif, Val-de-Marne, France
• Local Institution - 0031, Roma, Italy
• Local Institution - 0033, Verona, Italy
• Hospital Universitario Reina Sofia, Córdoba, Andalusia, Spain
• Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07195682.